Clinical trial NCT04720352: Prospective US Radiofrequency SUI Trial
Official title: PURSUIT: Prospective US Radiofrequency SUI Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Urinary Incontinence, Stress
Lead sponsor: Viveve Inc.
Sponsor class: INDUSTRY
First posted: 2021-01-22
Enrollment: 390
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pad Weight Test for up to 12 months post-treatment.

Detailed description: PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pad Weight Test for up to 12 months post-treatment. Secondary endpoints include:

* Percent of subjects who are responders in the 1-hour Pad Weight Test at 3- and 6-months post-treatment.
* Change from Baseline (CFB) to 3, 6- and 12-months post-treatment in the number of incontinence episodes as assessed by the 3-day bladder voiding diary.
* Percent of subjects with no incontinence episodes at 3, 6- and 12-months post-treatment as assessed by the 3-day bladder voiding diary.
* CFB to 3, 6, 9- and 12-months post-treatment in the I-QOL, ICIQ-UI-SF, PGI-I and MESA questionnaires.
* Percent CFB to 3, 6- and 12-months post-treatment in the 1-hour Pad Weight Test.

Eligibility criteria: Inclusion Criteria:

I.1 Able to understand and has voluntarily signed and dated the most current informed consent form (ICF) prior to initiation of any screening or study-specific procedures.

I.2 Willing to comply with study requirements and instructions.

I.3 Symptoms and diagnosis of stress urinary incontinence as determined by the following:

1. If there are mixed symptoms there must be a predominant stress component as determined by the 3-day diary results and MESA questionnaire
2. Patient-reported or history of SUI symptoms for \> 6 months prior to screening.
3. Positive Bladder Stress Test at the Baseline Visit.
4. Positive Q-tip test at the Baseline Visit (the observation of an angle that exceeds 30 degrees from horizontal in the opinion of the investigator or designee to denote hypermobility).
5. 1-hour pad weight at the Baseline Visit with a \>10 and \<50 g net increase from the pre-test pad weight.
6. Subjects must complete 3 days in the 3-day voiding diary during 3 consecutive days in the 7 days prior to the Baseline Visit, and subjects must report a minimum of 1 incontinence episode per day or \> 4 incontinence episodes over the 3 days as reported in the 3-day voiding diary.
7. For the Baseline 3-day diary, subjects must be compliant with recording events (i.e. void, leak or fluid intake) as determined through coordinator interview with the subject and review of voids and fluid intake reported in the diary compared to normal daily measurements.

I.4 Pre-menopausal females, ≥18 years of age. Premenopausal is defined as a woman who has had menstrual cycles over the previous 12 months or who is determined to be premenopausal by the PI or sub-investigator (e.g. premenopausal woman with hysterectomy).

I.5 Body mass index (BMI) of ≤35 kg/m² at the Screening Visit. I.6 Normal, or abnormal but not clinically significant (i.e., mild atrophy with rugae present, low grade prolapse), physical, pelvic and neurologic exam at the Baseline Visit as determined by the investigator.

I.7 Negative urine pregnancy test at the Baseline and Randomization Visits and subject agrees to not become pregnant during the study and uses an acceptable form of birth control started at least 3 months prior to screening (with the exception of double barrier contraception, where the 3-months required prior to screening does not apply).

1. Examples of acceptable forms of birth control include: abstinence from heterosexual vaginal intercourse, hysterectomy, bilateral tubal ligation, vasectomy, double barrier contraception (note that condom and spermicide is not considered double barrier contraception), intrauterine device or hormonal contraceptive.
2. Rhythm and withdrawal are not considered acceptable forms of contraception.

Exclusion Criteria:

E.1 Currently breastfeeding or have discontinued breastfeeding fewer than 6 months prior to screening.

E.2 Undergone other stress urinary incontinence treatment(s), excluding behavioral modifications started \>3 months prior to screening (e.g., Kegel exercises).

E.3 A MESA score of greater than 5 in sum on questions 10 - 12, or greater than 9 in sum on questions 10 - 15 at the screening visit (see appendix).

E.4 A post void residual measurement of greater than 150 ml as measured with ultrasound or bladder scanner at the screening visit.

E.5 Greater than 10 voids per day on average as measured with the 3-day diary at Baseline Visit.

E.6 Greater than 1 nocturia episode per day on average as measured with the 3-day diary at Baseline Visit.

E.7 Abnormal, clinically significant laboratory results at the Baseline Visit (as determined by the Investigator) that could impact the subject participation or evaluation for SUI. Retest is allowed with Sponsor approval.

E.8 Greater than 100 ounces of fluid consumed per day on average as measured with the 3-day diary at baseline Visit.

E.9 History of, or any current condition, illness, or surgery that might confound the results of urinary incontinence assessment, including, but not limited to:

1. Prominent (i.e., greater than Stage II pelvic organ prolapse as determined by a POP-Q evaluation (at Baseline) e.g., cystocele, rectocele
2. Neurological disorders (e.g., multiple sclerosis, Parkinson's disease, fibromyalgia)
3. Recurrent Urinary Tract Infections (UTI)
4. Current Urinary Tract Infection (UTI) as assessed by urine dipstick and associated urinary tract infection symptoms at the Baseline or Randomization Visit. If the subject has a UTI at the Baseline or Randomization Visit they may be treated with antibiotics, at the Investigator's discretion, and return within 7 days after UTI treatment completion.
5. Vesicoureteral reflux
6. Bladder stones
7. Bladder tumors
8. Interstitial cystitis E.10 Has any implantable electrical device \[e.g., implantable pacemaker, automatic implantable cardioverter-defibrillator (AICD)\].

E.11 A rectovaginal septum \<2 cm. E.12 Planning on future pregnancies after the Viveve procedure.

E.13 Medical or immunological condition, including, but not limited to:

1. Uncontrolled cardiovascular, respiratory, neoplastic, infectious, and/or endocrinological condition that could impact the subject's ability to complete the trial.
2. Uncontrolled diabetes defined as hemoglobin A1c \> 7%
3. Untreated chronic abdominal/pelvic pain disorder \[including, but not limited to, dyspareunia, vaginismus, endometriosis, significant vulvovaginal atrophy (VVA), genitourinary syndrome of menopause (GSM), irritable bowel syndrome, or Crohn's disease\].
4. Untreated medical condition or medication that, in investigator's opinion, may interfere with adequate wound healing response (e.g., congenital connective tissue disease) or the subject's ability to complete the clinical trial requirements.
5. Untreated active malignancy (with the exception of basal cell carcinoma of the skin) or undergoing treatment (using chemotherapeutic agents, radiation therapy, and/or cytostatic medications) that may interfere with adequate wound healing response or the subject's ability to complete the trial.
6. Untreated acute or chronic vaginal or vulvar disorder including, but not limited to, vulvovaginal atrophy/GSM; pain, including provoked/generalized vulvodynia, vulvar vestibulitis, dysesthetic vulvodynia, or vulvar dystrophy; current/chronic papulosquamous vulvar dermatoses (e.g., psoriasis, lichen planus, tinea cruris, lichen sclerosis, seborrheic dermatitis, contact/irritant dermatitis, lichen simplex, eczema); bullous dermatoses; systemic diseases with potential involvement of vulva; genital warts; past/current vaginal or vulvar radiotherapy or brachytherapy.
7. Active genital/pelvic infection (e.g., herpes, gonorrhea, chlamydia) observed on physical or pelvic exam at Baseline.
8. Active yeast infection. If the subject has an active vaginal yeast infection at the Baseline or Randomization Visit, they may be treated with an antifungal, at the Investigator's discretion, and return within 7 days after completion of vaginal yeast infection treatment.

E.14 Chronic use of anti-inflammatory drugs, including ibuprofen, aspirin, and oral steroids (excluding aspirin that is taken for cardiovascular prophylaxis).

E.15 Started taking any new medication, including herbal supplements and those taken in teas that potentially affects urination within 28 days prior to the Screening Visit, or had a change in the dosage of any medication that potentially affects urination within 28 days of the Screening Visit. Dosage should not change for the remainder of the study unless medically necessary.

E.16 Started or changed dose of local vaginal hormones \<6 weeks before screening.

E.17 Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal (including previous treatment with the Viveve System or any other genital radiofrequency treatment; injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement procedure).

E.18 Participated in another clinical study within 6 months of screening or is not willing to abstain from participating in other clinical studies for duration of trial.

E.19 Employed by Viveve or participating investigative sites.

Primary outcomes:
measure: 1-hour pad weight test
timeFrame: 12 months
Secondary outcomes:
measure: 3-day diary
timeFrame: 3, 6, and 12 months
measure: 1-hour pad weight test
timeFrame: 3 and 6 months
measure: Patient Global Impression of Improvement (PGI-I)
timeFrame: 3, 6, 9, and 12 months
measure: Medical, Epidemiologic, and Social aspects of Aging (MESA) questionnaire
timeFrame: 3, 6, 9, and 12 months
measure: International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF)
timeFrame: 3, 6, 9, and 12 months
measure: Incontinence Quality of Life (I-QOL)
timeFrame: 3, 6, 9, and 12 months
Other outcomes:
Locations:
city: Mobile
country: United States
facility: Coastal Clinical Research
state: Alabama
city: Tucson
country: United States
facility: Urological Associates of Southern Arizona, PC
state: Arizona
city: Long Beach
country: United States
facility: Long Beach Clinical Trials Services, Inc.
state: California
city: Washington
country: United States
facility: Emerson Clinical Research Institute
state: District of Columbia
city: Washington
country: United States
facility: IntimMedicine Specialists
state: District of Columbia
city: Lake City
country: United States
facility: Multi-Specialty Research Associates, Inc
state: Florida
city: Orange City
country: United States
facility: A Premier Medical Research of Florida
state: Florida
city: Tampa
country: United States
facility: Florida Urology Partners
state: Florida
city: Idaho Falls
country: United States
facility: Leavitt Clinical Research
state: Idaho
city: Wichita
country: United States
facility: Cypress Medical Research Center, LLC
state: Kansas
city: Owensboro
country: United States
facility: Research Integrity, LLC
state: Kentucky
city: Shreveport
country: United States
facility: Regional Urology, LLC
state: Louisiana
city: Owings Mills
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Maplewood
country: United States
facility: Minnesota Women's Care, P.A.
state: Minnesota
city: Missoula
country: United States
facility: Boeson Research
state: Montana
city: Omaha
country: United States
facility: Adult and Pediatric Urology
state: Nebraska
city: Garden City
country: United States
facility: AccuMed Research Associates
state: New York
city: West Seneca
country: United States
facility: Circuit Clinical
state: New York
city: Raleigh
country: United States
facility: Unified Women's Health Care of Raleigh
state: North Carolina
city: Winston-Salem
country: United States
facility: UWCR-Lyndhurst Clinical Research
state: North Carolina
city: Middleburg Heights
country: United States
facility: Clinical Research Solutions
state: Ohio
city: Jenkintown
country: United States
facility: The Clinical Trial Center, LLC
state: Pennsylvania
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
city: Myrtle Beach
country: United States
facility: Venus Gynecology, LLC
state: South Carolina
city: Houston
country: United States
facility: Advances In Health Research
state: Texas
city: Irving
country: United States
facility: Cedar Health Research
state: Texas
city: League City
country: United States
facility: Maximos OB/GYN
state: Texas
city: San Antonio
country: United States
facility: Urology San Antonio
state: Texas
city: Newport News
country: United States
facility: Health Research of Hampton Roads, Inc
state: Virginia
Study officials:
affiliation: Medical University of South Carolina
name: Eric S Rovner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vanderbilt University Medical Center
name: Roger R Dmochowski, MD
role: STUDY_DIRECTOR
References: